key: cord-1056029-th7p2l23 authors: Huntley, Kristen; Einstein, Emily; Postma, Terri; Thomas, Anita; Ling, Shari; Compton, Wilson title: Advancing emergency department–initiated buprenorphine date: 2021-06-16 journal: J Am Coll Emerg Physicians Open DOI: 10.1002/emp2.12451 sha: 07c6f2a2fcd7a8a54bf4feee734287c8ca968caf doc_id: 1056029 cord_uid: th7p2l23 Opioids are the main driver of drug overdose deaths in the United States, and there has been a marked increase in opioid‐related overdoses during the COVID‐19 public health emergency. Many emergency departments (EDs) across the country are implementing ED‐initiated buprenorphine programs, and this is a method to address and prevent opioid overdoses. Resources are available to overcome barriers and take action. In 2019, 70,630 drug overdose deaths occurred in the United States. 1, 2 Provisional data show that approximately 86,001 drug overdose deaths occurred in the 12 months ending in July 2020. 3 Emergency departments (EDs) are in a prime position to address the overdose crisis, and a key intervention is establishing community referral partners for follow-up care and starting medication for opioid use disorder (MOUD) in the ED. Treatment of opioid use disorder (OUD) with buprenorphine is associated with a lower risk of overdose and better outcomes. 4 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2021 The Authors. JACEP Open published by Wiley Periodicals LLC on behalf of American College of Emergency Physicians 1-month (1.1%) and 1-year (5.5%) mortality rates of patients treated in the ED for nonfatal opioid overdose are high. The first month, and particularly the first 2 days after overdose, is the highest risk period (0.25% died within 2 days). 6 ED initiation of buprenorphine/naloxone and referral to treatment for patients with moderate to severe OUD has been shown to improve engagement in treatment, resulting in less self-reported opioid use and less use of inpatient services at 30 days compared with brief behavioral intervention or usual care. 7 ED-initiated buprenorphine (EDIB) is cost-effective 8 and has an ongoing impact; more patients who receive medication for OUD in the ED are engaged in treatment at 2 months. 9 Initiation of buprenorphine in the ED has received support from major professional associations, 18 and an increasing number of EDs treat patients with OUD with buprenorphine and dispense take-home naloxone to at-risk patients and their companions. 19 The American Surveys of clinicians indicate concerns that include (1) limited training; (2) access to follow-up care, insurance coverage, and prior authorization requirements; (3) scope of practice and competing priorities; and (4) patient transportation limitations for follow-up care, perceptions of limited patient interest in treatment, and patient preference for alternative treatments. [30] [31] [32] Initial misgivings about implementation often include concerns that people with OUD will inundate EDs. Importantly, sites note that this is not the case, and research has shown that EDIB programs are not associated with increased rates of patients presenting with requests for treatment. 33 People also worry about potential diversion of medication; however, the risk of fatal overdose associated with not receiving medication outweighs the risk associated with potential diversion. 34 Research shows that facilitators of initiating buprenorphine in EDs include (1) education and training; (2) access to treatment; (3) support including care coordinators, social workers or peer counselors, pharmacist consultation, local protocols, and order sets; and (4) feedback on patient experiences. 32 Clinicians may dispense or administer buprenorphine in the ED but are currently required to apply for a Drug Addiction Treatment Act (DATA) 2000 X-waiver to prescribe buprenorphine. Free training and ongoing support are available through the Providers Clinical Support System, 35 and free emergency medicine-focused training is available through the ACEP. 36 There is momentum to remove the separate waiver that is required for buprenorphine prescribing for physicians, which could improve access to medication. 37, 38 A quality framework can guide efforts to improve care in EDs. 39, 40 Comprehensive efforts are needed that include starting MOUD, overdose education, and naloxone distribution. Structured quality improvement programs could require training and initiation of medication before hospital discharge for patients with moderate to severe OUD. Process quality measures could include the proportion of patients with OUD who are provided with buprenorphine before discharge from the ED. Pennsylvania introduced the first statewide financial incentive to engage patients with OUD in treatment after hospital discharge from the ED or inpatient care. In future years, hospitals participating in the program can earn payments for improvement in the rate of OUD follow-up treatment. 41 The ACEP Emergency Quality Network Opioid Initiative, 42 Yale, 43 the California Bridge Program, 24 With increased funding and attention to the overdose epidemic in recent years, community access to care is improving. 46, 47 However, the adoption of medications in some settings remains low, 48 there are regional differences in the distribution of medication, 49 and a large treatment gap remains. [50] [51] [52] Continuing efforts are needed to enhance access, and EDIB programs offer an opportunity to build connections with community clinicians and to engage people in treatment. New extended-release buprenorphine formulations may help to address concerns about the transition to follow-up care in the community. US Food and Drug Administration-approved buprenorphine and naloxone daily formulation products 53 can result in cravings near the end of a 24-hour cycle. A buprenorphine monthly extendedrelease injection supports long-term abstinence from illicit opioid use. New injectable extended-release buprenorphine-only formulations to be available in the US in 2021, which allow for immediate induction and treat symptoms for up to 7 days, then monthly, are ideally suited for use in EDs and could address many of the challenges that patients face more effectively than daily medication formulations. A weekly injection would allow consistent dosing and time to connect with outpatient follow-up care. New formulations promise a higher level of opioid receptor occupancy, and a higher steady blood level, which should reduce cravings and provide a consistent blockade of the effects of illicit opioids. 54 Solid linkages with physicians, physician assistants, advanced practice nurses, and nurse practitioners providing MOUD in the community who can see patients quickly are of the utmost importance. Telehealth technologies have the potential to enhance access to treatment for those limited in ability to attend appointments because of limited transportation options, burden of time and effort associated with frequent in-person clinic visits, or not having treatment available locally. 55, 56 Electronic health record integration of order sets or clinical decision support is needed to operationalize roles, processes, and policies. Referral processes need to be streamlined, and research has indicated that specific patient identifiers, encrypted emails, and electronic health records are the preferred methods of communication for these linkages. 57 Current research is limited in that studies have predominantly been conducted at academic medical centers with few studies conducted in community EDs. Gaps exist in our knowledge about patient attitudes toward MOUD and the best practices, protocols, and workflows for EDIB. 19, 58 Also, research is needed to improve real-time identification of at-risk patients using electronic health record machine learning and/or screening. 59, 60 Research on innovative payment models may be necessary to improve care and coverage for people with OUD. The CMS recently announced 2 new payment models 61,62 as the next steps in a multipronged strategy to combat the nation's opioid crisis. In addition, the CMS has committed $50 million to assist states 63 Opportunities exist in EDs to impact the morbidity and mortality associated with the opioid overdose epidemic. There is an urgent need to create more public demand for MOUD and to further engage the emergency medicine community and hospitals to address the overdose crisis. Many tools and resources are now available to address clinician concerns and assist EDs in initiating medication for OUD and facilitating linkage to community treatment. Issue brief: reports of increases in opioid related overdose and other concerns during covid pandemic Drug overdose deaths in the United States Provisional drug overdose death counts Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort The prescription opioid addiction treatment study: what have we learned One-year mortality of patients after emergency department treatment for nonfatal opioid overdose Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial Cost-effectiveness of emergency department-initiated treatment for opioid dependence. Addiction Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: outcomes during and after intervention Declaring a national emergency concerning the novel coronavirus disease (COVID-19) Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic Millennium health's signals Report™ COVID-19 special edition reveals significant changes in drug use during the pandemic CORONAVIRUS: overdose deaths have skyrocketed in Chicago, and the coronavirus pandemic may be making it worse POLICY: drug overdoses climb during COVID-19 pandemic Collision of the COVID-19 and addiction epidemics The adverse impact of COVID-19 on individuals with oud s the urgent need for reform to leverage emergency department-based treatment COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States ACMT Position Statement Buprenorphine Administration in the Emergency Department Management of opioid use disorder in the emergency department: a white paper prepared for the american academy of emergency medicine American College of Emergency Physicians (ACEP) American College of Emergency Physicians (ACEP) Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectivenessimplementation study (Project ED HEALTH) User-centred clinical decision support to implement emergency department-initiated buprenorphine for opioid use disorder: protocol for the pragmatic group randomised EMBED trial Substance Abuse and Mental Health Services Administration (SAMHSA) Emergency Department-Initiated Buprenorphine And Validation Network Trial (Ed-Innovation) (NIH HEAL Initiative) Project information: measuring improvement in the quality of ED-initiated treatment for OUD using observation Emergency medicine opioid data infrastructure: key venue to address opioid morbidity and mortality (Project CODE PRO-capturing opioid use disorder electronically and patient reported outcomes) Peer recovery support: a bridge to treatment for overdose survivors (NIH HEAL Initiative) Emergency Department Connection to Care with Buprenorphine for Opioid Use Disorder Barriers and facilitators for emergency department initiation of buprenorphine: a physician survey Emergency departmentsa 24/7/365 option for combating the opioid crisis Barriers and facilitators to clinician readiness to provide emergency department-initiated buprenorphine Rates of substance use disorder treatment seeking visits after emergency department-initiated buprenorphine Medications For Opioid Use Disorder Save Lives Overview of medications for opioid use disorder Zooming to an X-Waiver: a silver lining of the COVID-19 pandemic American College of Emergency Physicians. X-ing the X-Waiver: the fight continues Lawmakers urge Biden to back opioid-treatment measure A quality framework for emergency department treatment of opioid use disorder Emergency department-based opioid harm reduction: moving physicians from willing to doing Participation in a hospital incentive program for follow-up treatment for opioid use disorder E-QUAL Network Opioid Initiative: reducing opioid associated harm nidamed-medical-health-professionals/disciplinespecific-resources/emergency-physicians-first-responders/ initiating-buprenorphine-treatment-in-emergency-department The Centers for Medicare and Medicaid Services (CMS): Quality Improvement Organizations (QIO) Use of medication-assisted treatment for opioid use disorders in employer-sponsored health insurance: final report Examines access to medication assisted treatment under Medicaid Differences in availability and use of medications for opioid use disorder in residential treatment settings in the United States Rise and regional disparities in buprenorphine utilization in the United States Research reveals that thirty-nine percent of counties across the United States lack access to effective opioid use disorder treatment Development of a Cascade of Care for responding to the opioid epidemic Developing an opioid use disorder treatment cascade: a review of quality measures Substance Abuse and Mental Health Services Administration (SAMHSA) Depot buprenorphine injection in the management of opioid use disorder: from development to implementation Incorporating telemedicine as part of COVID-19 outbreak response systems Innovation during COVID-19: improving addiction treatment access A scalable, automated warm handoff from the emergency department to community sites offering continued medication for opioid use disorder: lessons learned from the EMBED trial stakeholders Utilizing buprenorphine in the emergency department after overdose Identifying patients for overdose prevention with ICD-9 classification in the emergency department Screening emergency department patients for opioid drug use: a qualitative systematic review CMS announces new model to address impact of the opioid crisis for children Maternal Opioid Misuse (MOM) model CMS commits $50 million to assist states with substance use disorder treatment and recovery Advancing emergency department-initiated buprenorphine All authors contributed to the development and writing of the article.The authors acknowledge Dr. Douglas Olson for his insights, expertise, and thoughtful reviews. The authors acknowledge CarolAnne Saunders for her assistance with preparing the reference section. The authors declare no conflict of interest.